Drug Trial Radar · NCT01402492
Cocaine Use Reduction With Buprenorphine
Last checked: Nov 20, 2026Latest source record: Oct 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
302
Actual
Start
Sep 2011
Primary completion
Jan 2013
Study completion Mar 2013
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA); The Emmes Company, LLC
- First posted
- Jul 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to investigate the safety and effectiveness of buprenorphine in the presence of naltrexone for the treatment of cocaine dependence.
Conditions
- Cocaine Dependence
Interventions
Buprenorphine + NaltrexoneDrug
Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
Placebo + NaltrexoneDrug
Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cocaine Use Days as Measured by Self-report, Corroborated by Thrice-weekly Urine Drug ScreensTime frame: final 30 days of Treatment Phase, study days 25-54
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
UCLA Integrated Substance Abuse Programs (ISAP)
Los Angeles, California
Bay Area Addiction Research and Treatment (BAART)
San Francisco, California
Addiction Research and Treatment Services (ARTS)
Denver, Colorado
Howard University Hospital
Washington D.C., District of Columbia
Atlanta VA Medical Center
Atlanta, Georgia
Bellevue Hospital Center
New York, New York
Albert Einstein College of Medicine - Division of Substance Abuse
The Bronx, New York
Maryhaven
Columbus, Ohio
CODA, Inc.
Portland, Oregon
South Texas Veterans Health Care System
San Antonio, Texas
Recovery Centers of King County (RCKC)
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.